IGC Pharma

IGC · NYSE American

$0.245+$0.003 (+1.24%)TodayMarket closed ·
Prev close $0.242

Key indicators

IGC profitability and balance sheet ratios

EPS -$0.0293 in Q2 FY26, against -$0.0193 a year earlier.

EPS by quarter
PeriodEPS
Sep 2024-$0.0226
Q3 FY25-$0.0236
Q4 FY25-$0.015
Q2 FY25-$0.0193
Sep 2025-$0.0201
Dec 2025-$0.0076
Q1 FY26-$0.0245
Q2 FY26-$0.0293

Where the money went

Q2 FY26, from revenue to net income

IGC Pharma brought in $0.3M of revenue in Q2 FY26, −19.2% on a year earlier. It made a net loss of $2.9M.

Revenue
$0.3M
Costs, expenses and taxes
$3.2M
Net income
−$2.9M
Net margin
-1107.9%

Income statement

Revenue and profit by reporting period

Revenue
Net income
IGC income statement, quarterly
Line itemQ2 FY25Q1 FY26Q2 FY26
Revenue$0.3M$0.3M$0.3M
Gross profit$0.2M$0.1M$0.0M
Operating income−$1.9M−$2.5M−$2.8M
Net income−$1.6M−$2.4M−$2.9M
Diluted EPS-$0.02-$0.02-$0.03

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
IGC balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$9.7M$9.2M$9.5M
Total liabilities$2.3M$3.1M$3.4M
Shareholder equity$7.4M$6.1M$6.1M
Cash and short-term investments$0.9M$0.2M$0.4M
Total debt$0.1M$0.9M$1.1M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
IGC cash flow, quarterly
Line itemQ2 FY25Q1 FY26Q2 FY26
Operating cash flow−$1.4M−$1.2M−$1.4M
Investing cash flow$0.6M−$0.2M−$0.3M
Financing cash flow$0.9M$0.7M$1.7M
Capital expenditure−$0.0M−$0.0M−$0.0M
Free cash flow−$1.4M−$1.2M−$1.4M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.